Over the past decade, the cell and gene therapy industry has witnessed milestone breakthroughs, with successive approvals of CAR-T, TIL, TCR-T, gene therapy, mRNA, and gene editing therapies. Recently, in vivo CAR-T has garnered significant attention, prompting increased investments from international giants such as AstraZeneca, AbbVie, and Gilead. These innovations have not only redefined treatment paradigms for diseases but also brought unprecedented hope to millions of patients and their families worldwide who once faced untreatable conditions.

The CGCS 2026 - 7th International Cell & Gene Therapy China Summit & Exhibition, hosted by Chujie Bio, is projected to bring together 200+ global top-tier speakers, 200+ leading exhibitors, 5,000+ industry professionals for offline participation, and 10,000+ online global viewers, striving to inject more cooperation and opportunities into the cell and gene therapy industry.